With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Healthcare is undervalued despite being a top sector for earnings growth. Read more on attractive investments among ...

Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100 ...

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...

Unrestricted funds (educational activities): Abbott, Dexcom, Eli Lilly, Medtronic, Merck ... but it’s not totally unprecedented in the history of pharmaceutical blockbusters. The volume of ...

Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said ...

Eli Lilly and Company is expanding its manufacturing footprint in Ireland with a $1.8B investment to boost production of ...

New investment will enhance global medicine production, benefiting millions of patients worldwide ...

As a part of this expansion, Lilly will create another 150 jobs for highly skilled workers in Limerick, bringing its total ...